Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Post-approval studies have become the backbone of monitoring how well Alzheimer’s drugs actually work in real-world patient populations. After lecanemab (Leqembi) and donanemab (Kisunla) received FDA approval, regulatory agencies and patient registries began implementing rigorous surveillance systems to track their effectiveness, safety profile, and long-term impact. These ongoing studies go far beyond the initial clinical trials, involving thousands of patients treated outside controlled research settings where treatment responses, side effects, and outcomes vary considerably based on individual health factors. The monitoring process now includes regular brain MRI scans, blood biomarker testing, and data collection through national registries like ALZ-NET in the United States and coordinated international systems in Japan and other countries.
For example, lecanemab patients now undergo MRI scans at baseline and before specific infusions (at infusions 3, 5, 7, and 14), creating a detailed picture of how the drug affects brain structure and potential complications over time. This systematic approach reflects a critical lesson from drug development: what works in a tightly controlled trial with selected patients often behaves differently when given to diverse populations across countless clinics and hospitals. Regulatory agencies learned from previous drugs that initial approval data doesn’t tell the complete story. Post-approval monitoring has become the tool for answering questions that emerge only after thousands of patients receive treatment—questions about effectiveness in different age groups, interaction with other medications, and which patients face the highest risk of serious side effects.
Table of Contents
- How Are Alzheimer’s Drug Registries Tracking Real-World Effectiveness?
- What Monitoring Protocols Keep Patients Safe During Treatment?
- What Do Post-Approval Studies Reveal About Side Effects and Safety Risks?
- Why Do Doctors Now Test for APOE ε4 Before Starting Alzheimer’s Drugs?
- What Happens When ARIA Develops During Treatment?
- What New Treatment Combinations Are Being Tested?
- How Are Personalized Medicine Approaches Reshaping Alzheimer’s Drug Monitoring?
- Conclusion
How Are Alzheimer’s Drug Registries Tracking Real-World Effectiveness?
Patient registries have emerged as the cornerstone of post-marketing surveillance for anti-amyloid therapies. The ALZ-NET registry serves as a key framework for real-world effectiveness tracking in the United States, collecting data from patients treated at participating centers and hospitals. This approach captures what happens to diverse patient populations—older adults, people with multiple health conditions, and those taking various medications—rather than just the relatively healthy, selected groups enrolled in initial clinical trials. Japan has taken a similar approach with a national registry supported through public-private partnership, designed to promote rigorous data collection and enable continuous evaluation of risk-benefit profiles. These international systems allow researchers to compare how the drugs perform across different healthcare systems, populations, and treatment protocols.
For instance, differences in how frequently patients receive brain imaging, variations in medication management, and diverse patient demographics all influence real-world outcomes and side effect profiles. When one registry identifies a concerning safety signal, other registries can rapidly investigate whether the same pattern appears in their populations, triggering faster regulatory action if needed. The critical advantage of these registries is their ability to answer questions about subgroups. Initial trials might include only 500 to 1,500 patients, but registries now track tens of thousands. This makes it possible to understand how a drug performs specifically in patients over 85, in those with early-stage dementia versus mild cognitive impairment, or in people with other neurological conditions. The limitation, however, is that registry data collection depends on clinician participation and consistent reporting—some centers contribute more detailed information than others, and data quality can vary.
What Monitoring Protocols Keep Patients Safe During Treatment?
Lecanemab and donanemab require frequent monitoring with brain MRI scans because these drugs target amyloid in the brain, and the imaging detects amyloid-related imaging abnormalities (ARIA)—changes that appear on MRI and can signal potential problems. For lecanemab, the FDA-recommended protocol includes a baseline MRI scan, then additional scans before the 3rd, 5th, 7th, and 14th intravenous infusions. This frequent imaging schedule exists because ARIA can develop without causing noticeable symptoms, making MRI the only way to detect problems early. Donanemab uses a similar but slightly different monitoring schedule, with scans recommended prior to the 2nd, 3rd, 4th, and 7th infusions, plus a 12th dose scan for higher-risk patients and anytime a clinician suspects ARIA based on symptoms or cognitive changes.
The specific timing differences reflect findings from post-approval data showing that certain doses carry higher risk periods. One important limitation of this approach is the burden on patients and healthcare systems—frequent MRI scans are time-consuming, expensive, and not universally available in all communities. For elderly patients with limited mobility or significant anxiety about medical procedures, the monitoring schedule itself becomes a barrier to receiving treatment. Recent updates have added another layer: lecanemab now has an FDA-approved subcutaneous formulation called Leqembi Iqlik, designed for maintenance treatment to improve administration flexibility. This new option reduces the need for frequent intravenous infusions but still requires the same rigorous MRI monitoring schedule, so the scanning burden remains unchanged despite the easier injection method.
What Do Post-Approval Studies Reveal About Side Effects and Safety Risks?
Post-approval studies have revealed that amyloid-lowering drugs carry significantly higher risks for amyloid-related imaging abnormalities than early trials suggested. Meta-analysis data comparing lecanemab and donanemab to placebo groups shows that treated patients face a relative risk of ARIA that is 4.35 times higher than control groups. Both ARIA-E (swelling in the brain, called amyloid-related imaging abnormalities affecting the cortex) and ARIA-H (microhemorrhages, small bleeding in the brain) occur more frequently in treated groups, with ARIA-E being more common overall. One critical finding from post-approval monitoring is that donanemab’s new, modified titration dosing schedule can reduce ARIA-E risk substantially. The modified dosing arm showed an ARIA-E frequency of 13.7% compared with 23.7% in the standard dosing arm—a significant reduction achieved by adjusting how quickly patients escalate to full doses.
This discovery emerged directly from post-approval data analysis and has now been incorporated into the FDA-approved label, demonstrating how real-world monitoring leads to safer treatment approaches. However, the warning here is important: even with optimized dosing, ARIA remains a real concern affecting roughly 1 in 8 to 1 in 4 patients depending on dosing approach and individual risk factors. The risk of ARIA-H (microhemorrhages) carries additional weight because brain bleeding can potentially cause strokes or permanent cognitive damage. While many small microhemorrhages cause no obvious symptoms, the long-term consequences of accumulating brain bleeding remain uncertain. This uncertainty is why post-approval studies must continue for years after drug approval, tracking whether patients with ARIA-H experience cognitive decline, future strokes, or other complications.
Why Do Doctors Now Test for APOE ε4 Before Starting Alzheimer’s Drugs?
Pre-treatment biomarker testing has become standard practice because post-approval studies revealed that ARIA risk is substantially greater in people carrying the APOE ε4 genetic variant. Both lecanemab and donanemab labels now recommend testing for APOE ε4 status before treatment initiation. This genetic test helps identify which patients face the highest risk of developing brain swelling or microhemorrhages during treatment, allowing clinicians to make more informed decisions about whether the drug’s benefits outweigh its risks for that individual. For patients without APOE ε4, the absolute ARIA risk is lower, making treatment a more straightforward decision. But for APOE ε4 carriers—particularly those who carry two copies of the ε4 variant—the risk profile becomes more complex.
A 78-year-old patient without ε4 might have a 10% chance of developing ARIA-E, while the same patient with ε4 could face a 25-30% risk. This comparison fundamentally changes the decision-making process. Some clinicians now counsel high-risk patients more cautiously or recommend even more frequent monitoring for those who choose to proceed. The limitation of this approach is that APOE testing doesn’t perfectly predict ARIA risk—some ε4 carriers never develop imaging abnormalities, while occasionally people without ε4 develop ARIA. Additionally, genetic testing introduces new ethical questions: should test results influence insurance coverage decisions or employment prospects? Post-approval surveillance systems must continue monitoring whether using APOE ε4 status as a gating criterion actually improves outcomes by preventing side effects or simply excludes patients who might have benefited from treatment.
What Happens When ARIA Develops During Treatment?
ARIA detection through MRI monitoring often precedes symptoms, meaning most patients develop imaging changes without knowing it. When radiologists identify ARIA-E on a scan, patients may experience headache, confusion, or memory problems—or they may feel completely normal. The uncertainty creates clinical dilemmas: some patients opt to continue treatment hoping the imaging abnormalities resolve, others pause treatment, and some decide to stop completely. Post-approval studies track these decisions and their outcomes, building a picture of which patients ultimately benefit despite ARIA and which experience lasting cognitive changes. ARIA-H, the microhemorrhage type, requires more caution. A single small microhemorrhage on MRI might be clinically silent, but accumulating hemorrhages raise concerns about future stroke risk or progressive cognitive damage.
One limitation of current monitoring is that we don’t yet know the safe threshold—how many microhemorrhages can develop before the cumulative damage becomes concerning? Post-approval surveillance continues collecting long-term follow-up data to answer this question. Another warning: post-approval studies have identified that patients with existing cerebral amyloid angiopathy (a condition where amyloid deposits in blood vessel walls, increasing bleeding risk) face substantially elevated ARIA-H risk when treated with lecanemab or donanemab. Clinical management of ARIA has evolved based on post-approval experience. Most centers now pause or temporarily stop the infusions if ARIA-E develops, then resume after imaging improves. For ARIA-H, the approach is more conservative—many clinicians recommend discontinuing treatment permanently. These protocols continue evolving as post-approval data accumulates, with registries tracking outcomes of different management strategies to refine best practices.
What New Treatment Combinations Are Being Tested?
Post-approval monitoring systems aren’t just tracking existing treatments—they’re also supporting research into how these drugs might combine with other therapies for greater benefit. In May 2025, investigators at Banner Health registered a Phase 2/3 trial testing donanemab combined with RG6289, a gamma-secretase inhibitor, in people with autosomal-dominant Alzheimer’s disease, with enrollment beginning in January 2026. This combination approach reflects the thinking that blocking multiple pathways simultaneously—removing existing amyloid while preventing new amyloid production—might produce better results than single-drug therapy.
Post-approval registries provide a natural foundation for these combination studies because they’ve already established baseline data on how patients respond to monotherapy. The networks of clinics participating in registries like ALZ-NET can rapidly recruit and monitor patients in new trials, accelerating the research process. However, adding a second medication also multiplies the potential for side effects, meaning these combination trials require equally rigorous post-approval monitoring.
How Are Personalized Medicine Approaches Reshaping Alzheimer’s Drug Monitoring?
The field is moving toward more personalized approaches to Alzheimer’s treatment based on post-approval findings. The Alzheimer’s Association convened a workgroup to propose the TRAC framework for better monitoring efficacy and safety of anti-amyloid treatments, with emphasis on future studies investigating optimal treatment regimens and personalized medicine approaches.
Rather than a one-size-fits-all dosing schedule, TRAC emphasizes matching treatment intensity and monitoring frequency to individual risk profiles. This framework recognizes that a 70-year-old patient without APOE ε4 and no cerebral amyloid angiopathy might safely receive standard dosing with routine monitoring, while an 82-year-old ε4 carrier with existing small vessel disease might benefit from modified dosing schedules and more frequent imaging. Post-approval surveillance systems are accumulating the data needed to validate these personalized approaches, potentially making Alzheimer’s drug treatment safer and more effective than current one-size-fits-all protocols.
Conclusion
Post-approval studies have transformed how Alzheimer’s drugs are monitored in real-world practice, moving far beyond initial clinical trial data to track actual patient outcomes across diverse populations. Through registries like ALZ-NET and international monitoring systems, clinicians now understand that these medications work for many patients in slowing cognitive decline, but they also carry significant risks of brain imaging abnormalities that require careful surveillance.
The regular monitoring protocols—MRI scans, biomarker testing, and data collection in patient registries—reflect a commitment to identifying and managing side effects early while continuing to learn how to optimize treatment for each person. If you’re considering an amyloid-lowering therapy like lecanemab or donanemab, ask your neurologist about pre-treatment testing (particularly APOE ε4 status), discuss the MRI monitoring schedule and what results might mean for your treatment plan, and understand the risk-benefit comparison specific to your own health situation. Post-approval research continues evolving these drugs and our understanding of them, so staying informed through your healthcare team ensures you benefit from the most current safety and effectiveness information available.
You Might Also Like
- Novel Regulatory Pathways Facilitate Alzheimer’s Drug Approvals
- Outcome Measurement Tools Standardize Alzheimer’s Treatment Assessment
- Multi-Analyte Testing Approaches Strengthen Alzheimer’s Diagnostics
For more, see NIH MedlinePlus — cognitive testing.
